fouremm - 4) There is financial clairity if apabetalone becomes a sellable drug, $2000 to $5000 per patient per year with a market of 5 million to 10 million patients. Beacon gives us an $8.50 valuation with just 2% market penetration. If the drug comes anywhere close to what we have been lead to believe we would likely get substantially greater than 2% penetration. There is absolutely no clairity on the financials after the recently borrowed money runs out. 

All IMO

tada